Translational Research

The Vancouver Prostate Centre is heavily focused on translational research, which is the ability to move laboratory discoveries through the checks and balances into clinical trials, and eventually to develop these research findings into new and more effective treatments.

PC-TRiADD is the Vancouver Prostate Centre’s Translational Research Initiative for Accelerated Discovery and Development.

This initiative dives down to the molecular level to understand prostate cancer progression and treatment resistance and uses that information to develop new services and products to improve cancer outcomes.

Funded by the Government of Canada as a Centre of Excellence for Commercialization and Research (CECR), PC-TRiADD also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as drug discovery, preclinical testing, tumour biology and clinical research.

Click here to read PC-TRiADD's 2016-2017 annual report (opens in new window)

PC-TRiADD 2016-17 Annual Report

 

Research2Reality interview with Dr. Gleave

Dr. Gleave discusses the role of research in the development of new drug combinations and personalized treatments for prostate cancer on Research2Reality's Orange Chair Sessions (2.5 minutes).

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Movember Foundation 2018

Movember 2018

The Movember Foundation's fundraiser runs from November 1 to 30.  Click here to donate to The Vancouver Prostate Centre team as we join teams across Canada to raise funds for men's health research in the areas of prostate cancer, testicular cancer, mental health and suicide prevention.

Employment

Work at the Vancouver Prostate Centre

Tuesday, November 27, 2018

An innovative new study advances personalized medicine for prostate cancer patients

Drs Chi and Wyatt
Tuesday, October 23, 2018

Three researchers receive Prostate Cancer Canada & Movember Foundation grants for biomarker development